Skip to main content

Table 7 Tumor staging before and after letrozole treatment (Safety population (N = 32), number and percentage of patients)

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

Clinical stage Baseline Individual End
T1a -- 1 (3.1%)
T1b -- 1 (3.1%)
T1c -- 7 (21.9%)
T2 23 (71.9%) 19 (59.4%)
T3 5 (15.6%) --
T4a 1 (3.1%) --
T4b 3 (9.4%) --
Missing -- 4 (12.5%)